Golimumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Golimumab comprises 264 peer-reviewed publications across 15 journals, 33 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Colitis, Ulcerative, Arthritis, Rheumatoid, Spondylitis, Ankylosing, and Arthritis, Psoriatic. Most recent publication: Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study., Inflamm Bowel Dis, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK).
    Weinstein CLJ, Sliwinska-Stanczyk P, Hála T, et al. · Rheumatology (Oxford) · 2023
    PubMed: PMID 36919768 · NCT03253796 · Spondylarthritis
  2. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.
    Stefanovic S, Detrez I, Compernolle G, et al. · Eur J Gastroenterol Hepatol · 2021
    PubMed: PMID 32804854 · NCT04156984 · Colitis, Ulcerative
  3. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
    Sieper J, van der Heijde D, Dougados M, et al. · Arthritis Rheumatol · 2016
    PubMed: PMID 26139307 · NCT01453725 (GO-AHEAD) · Spondylitis, Ankylosing
  4. Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial.
    Proft F, Muche B, Listing J, et al. · BMJ Open · 2018
    PubMed: PMID 28601821 · NCT02758782 (CONSUL) · Spondylitis, Ankylosing
  5. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.
    Magro F, Lopes S, Silva M, et al. · Ther Adv Gastroenterol · 2022
    PubMed: PMID 31516554 · NCT02318667 (EVOLUTION) · Colitis, Ulcerative
  6. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
    Magro F, Lopes S, Silva M, et al. · J Crohns Colitis · 2020
    PubMed: PMID 30989180 · NCT02318667 (EVOLUTION) · Colitis, Ulcerative
  7. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
    Combe B, Dasgupta B, Louw I, et al. · Ann Rheum Dis · 2014
    PubMed: PMID 23740226 · NCT00975130 (GO-MORE) · Arthritis, Rheumatoid
  8. Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial.
    Krabbe S, Renson T, Jans L, et al. · Rheumatology (Oxford) · 2023
    PubMed: PMID 36200875 · NCT01426815 (CRESPA)

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00264537Arthritis, RheumatoidChange From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 52
Baseline and Week 52
Combined Golimumab + Methotrexate0.41 Scores on a scale (±3.929 Standard Deviation)
Group 1: Placebo + Methotrexate1.37 Scores on a scale (±4.555 Standard Deviation)
Group 2: Golimumab 100 mg + Placebo1.25 Scores on a scale (±6.155 Standard Deviation)
Group 3: Golimumab 50 mg + Methotrexate0.74 Scores on a scale (±5.233 Standard Deviation)
Group 4: Golimumab 100 mg + Methotrexate0.07 Scores on a scale (±1.833 Standard Deviation)
NCT00264537Arthritis, RheumatoidNumber of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24
Week 24
Combined Golimumab + Methotrexate122 Participants
Group 1: Placebo + Methotrexate47 Participants
Group 2: Golimumab 100 mg + Placebo52 Participants
Group 3: Golimumab 50 mg + Methotrexate64 Participants
Group 4: Golimumab 100 mg + Methotrexate58 Participants
NCT00264550
GO-FORWARD
Arthritis, RheumatoidChange From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 24
Baseline (Week 0) and Week 24
Combined Golimumab + Methotrexate0.4375 Units on a scale
Group 1: Placebo + Methotrexate0.1250 Units on a scale
Group 2: Golimumab 100 mg + Placebo0.1250 Units on a scale
Group 3: Golimumab 50 mg + Methotrexate0.3750 Units on a scale
Group 4: Golimumab 100 mg + Methotrexate0.5000 Units on a scale
NCT00264550
GO-FORWARD
Arthritis, RheumatoidNumber of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 14
Week 14
Combined Golimumab + Methotrexate99 Participants
Group 1: Placebo + Methotrexate44 Participants
Group 2: Golimumab 100 mg + Placebo59 Participants
Group 3: Golimumab 50 mg + Methotrexate49 Participants
Group 4: Golimumab 100 mg + Methotrexate50 Participants
NCT00265083Spondylitis, AnkylosingAssessment in Ankylosing Spondylitis 20 Responders at Week 14
Week 14
Combined: Groups II & III166 Participants
Group I: Placebo17 Participants
Group II: Golimumab 50 mg82 Participants
Group III: Golimumab 100 mg84 Participants
NCT00265096
GO-REVEAL
Arthritis, PsoriaticAmerican College of Rheumatology (ACR) 20 Response at Week 14
Baseline (Week 0), Week 4, Week 8 and Week 14
Combined: Group II & III140 Participants
Group I: Placebo10 Participants
Group II: Golimumab 50 mg74 Participants
Group III: Golimumab 100 mg66 Participants
NCT00265096
GO-REVEAL
Arthritis, PsoriaticChange From Baseline in Total Radiographic Scores of the Hands and Feet at Week 24
Baseline and Week 24
Combined: Group II & III-0.09 Scores on a scale (±1.315 Standard Deviation)
Group I: Placebo0.27 Scores on a scale (±1.259 Standard Deviation)
Group II: Golimumab 50 mg-0.16 Scores on a scale (±1.309 Standard Deviation)
Group III: Golimumab 100 mg-0.02 Scores on a scale (±1.322 Standard Deviation)
NCT00299546Arthritis, RheumatoidAmerican College of Rheumatology (ACR) 20 Response at Week 14.
Week 14
Combined Golimumab105 participants
Group 1: Placebo27 participants
Group 2: Golimumab 50 mg51 participants
Group 3: Golimumab 100 mg54 participants
NCT00361335Arthritis, RheumatoidNumber of Participants With an American College of Rheumatology (ACR) 50 Response at Week 14
Week 0 to Week 14
Group I: 2mg/kg Golimumab+ MTX28 Participants
Group II: 2mg/kg Golimumab Only16 Participants
Group III: 4mg/kg Golimumab + MTX27 Participants
Group IV: 4mg/kg Golimumab Only25 Participants
Group V: IV Placebo + MTX17 Participants
Group VI: Combined Groups I and III55 Participants
Group VII: Combined Groups II and IV41 Participants
NCT00487539Colitis, UlcerativeNumber of Participants With Clinical Response at Week 6
Baseline, Week 6
Golimumab 200 mg -> 100 mg129 Participants
Golimumab 400 mg -> 200 mg141 Participants
Placebo76 Participants
NCT00488631Colitis, UlcerativeNumber of Participants in Clinical Response Through Week 54
Induction Baseline, Week 0 through Week 54
GLM-I-Rsp-Golimumab 100 mg Maintenance75 Participants
GLM-I-Rsp-Golimumab 50 mg Maintenance71 Participants
Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance48 Participants
NCT00488774Colitis, UlcerativeNumber of Participants With Clinical Response
Week 6
Golimumab 1 mg Per kg22 Participants
Golimumab 2 mg Per kg33 Participants
Golimumab 4 mg Per kg32 Participants
Placebo22 Participants
NCT00973479Arthritis, RheumatoidProportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14
Week 14
Group I: Placebo + Methotrexate (MTX)24.9 Percentage of Participants
Group II: Golimumab 2 mg/kg + Methotrexate (MTX)58.5 Percentage of Participants
NCT00975130
GO-MORE
Arthritis, RheumatoidNumber of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Month 6
Month 6
GLM50-SC2692 Participants
NCT00975130
GO-MORE
Arthritis, RheumatoidNumber of Participants Experiencing Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at the Start of Month 11 and End of Month 12
Start of Month 11, End of Month 12
IV-GLM2/SC-GLM5058 Participants
IV-GLM2/SC-GLM5059 Participants
SC-GLM5067 Participants
SC-GLM5064 Participants
NCT01004432Arthritis, RheumatoidPercentage of Participants Achieving Erythrocyte Sedimentation Rate (ESR)-Based American College of Rheumatology [ACR] 20 Response at Week 14
Week 14
OL Overall Group: Golimumab 50 mg SC + MTX34.9 percentage of participants
NCT01230827Arthritis, JuvenilePercentage of Participants With American College of Rheumatology (ACR) 30 Response at Week 16 Who Did Not Experienced a Flare of Disease Through Week 48
Week 16 through Week 48
CNTO 148 (Golimumab)59.0 Percentage of Participants
Placebo52.6 Percentage of Participants
NCT01248780Arthritis, RheumatoidAmerican College of Rheumatology (ACR) 20 Response, Using CRP (C-reactive Protein), at Week 14
Week 14
Group I: Placebo + MTX21 Number of participants
Group II: Golimumab 50 mg + MTX54 Number of participants
NCT01248793Spondylitis, AnkylosingAssessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14
Week 14
Group I: Placebo26 Participants
Group II: Golimumab 50 mg53 Participants
NCT01453725
GO-AHEAD
Spondylitis, AnkylosingPercentage of Participants Achieving an Assessment in Ankylosing Spondylitis (ASAS) 20 Response at Week 16
Week 16
Golimumab→Golimumab71.1 Percentage of Participants
Placebo→Golimumab40.0 Percentage of Participants
NCT01453725
GO-AHEAD
Spondylitis, AnkylosingPercentage of Participants Who Discontinued Study Drug Due to an AE
Up to 16 weeks for Part 1; Week 16 through up to 48 weeks for Part 2
Golimumab→Golimumab2.1 Percentage of Participants
Golimumab→Golimumab1.1 Percentage of Participants
Placebo→Golimumab1.0 Percentage of Participants
Placebo→Golimumab2.1 Percentage of Participants
NCT01453725
GO-AHEAD
Spondylitis, AnkylosingPercentage of Participants Who Experienced at Least One Adverse Event (AE)
Up to 16 weeks for Part 1: Week 16 through up to 60 weeks for Part 2 (Up to 12 weeks after last dose of study drug)
Golimumab→Golimumab41.9 Percentage of Participants
Golimumab→Golimumab41.2 Percentage of Participants
Placebo→Golimumab47.0 Percentage of Participants
Placebo→Golimumab54.2 Percentage of Participants
NCT01863771Colitis, UlcerativeNumber of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score
Up to Week 54
Golimumab18 participants
Placebo6 participants
NCT02065713
GO-DACT
Arthritis, PsoriaticDactylitis Severity Score (DSS)
From baseline to week 24
Golimumab in Combination With Methotrexate-5 change of score on a scale
Placebo in Combination With Methotrexate-2 change of score on a scale
NCT02181673Arthritis, PsoriaticPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14
Week 14
Golimumab75.1 Percentage of Participants
Placebo21.8 Percentage of Participants
NCT02186873Spondylitis, AnkylosingPercentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16
Week 16
Group 1: Placebo Then Golimumab26.2 Percentage of Participants
Group 2: Golimumab73.3 Percentage of Participants
NCT02277444
GO-VIVA
Arthritis, JuvenileBayesian Area Under Curve at Steady State (AUCss) Over an 8-week Dosing Interval at Week 28
Week 28
Golimumab399 micrograms*day/milliliter (mcg*day/mL)
NCT02277444
GO-VIVA
Arthritis, JuvenileSerum Trough Concentration (C-trough) of Golimumab
Week 28
Golimumab0.50 micrograms per milliliter (mcg/mL) (±0.427 Standard Deviation)
NCT02437162Axial SpondyloarthritisPercentage of Participants Who Achieved an Assessment of Spondyloarthritis International Society (ASAS) 40 Response at Week 24
Week 24
Placebo28.4 Percentage of participants
Ustekinumab 45 Milligram (mg)31.0 Percentage of participants
Ustekinumab 90 mg28.1 Percentage of participants
NCT02438787Spondylitis, AnkylosingPercentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 24
Week(W) 24
Placebo12.3 Percentage of participants
Ustekinumab 45mg19.2 Percentage of participants
Ustekinumab 90mg26.9 Percentage of participants
NCT03270501
GO-GUT
Axial SpondyloarthritisProportion of Patients Achieving Sustained Clinical Remission
Upon end of trial for individual patient, between 28 and 52 weeks.
Arm 1: NSAIDs With Possible Step-up to Golimumab34 Participants
NCT03596645
PURSUIT 2
Colitis, UlcerativePercentage of Participants With Clinical Remission at Week 6 as Assessed by the Mayo Score
Week 6
Group 1: Golimumab31.9 Percentage of participants
NCT04108468
GOLMePsA
Arthritis, PsoriaticPsoriatic Arthritis Disease Activity Score (PASDAS) at 24 Weeks
24 weeks
Golimumab & Methotrexate2.70 score on a scale (±1.38 Standard Deviation)
Methotrexate3.09 score on a scale (±1.32 Standard Deviation)

Publications by year

1985–2026: 264 publications.

1985
1
2002
2
2004
3
2005
1
2006
2
2007
6
2008
5
2009
4
2010
9
2011
12
2012
14
2013
13
2014
18
2015
18
2016
22
2017
26
2018
22
2019
18
2020
26
2021
10
2022
14
2023
10
2024
2
2025
3
2026
3

Publications by indication

Colitis, Ulcerative (155)

  • Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study.
    Inflamm Bowel Dis · 2026 · PMID 41503939 · NCT03596645
  • EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
    Ther Adv Gastroenterol · 2026 · PMID 31205485 · NCT05313620
  • New Interleukin-23 Antagonists' Use in Crohn's Disease.
    Pharmaceuticals (Basel) · 2025 · PMID 40283885 · NCT07495644
  • Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions.
    Clin Pharmacol Ther · 2024 · PMID 38488354 · NCT03662542
  • Immunogenicity of biologics in inflammatory bowel disease.
    Ther Adv Gastroenterol · 2024 · PMID 29383030 · NCT07495644

Arthritis, Rheumatoid (49)

  • Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study.
    BioDrugs · 2026 · PMID 41182658 · NCT05842213
  • Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study.
    Patient Prefer Adherence · 2025 · PMID 40585577 · NCT03729349
  • Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study.
    BMC Rheumatol · 2023 · PMID 36973741 · NCT02728934
  • Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study.
    Rheumatol Ther · 2023 · PMID 36820983 · NCT02728934
  • Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Clin Ther · 2022 · PMID 35183373 · NCT00973479

Spondylitis, Ankylosing (18)

  • Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
    Rheumatol Ther · 2023 · PMID 37322274 · NCT02186873
  • Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension.
    Rheumatology (Oxford) · 2022 · PMID 33878154 · NCT01453725
  • Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.
    J Clin Rheumatol · 2022 · PMID 35653615 · NCT02186873
  • The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
    Clin Rheumatol · 2021 · PMID 32926247 · NCT02186873
  • Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Rheumatology (Oxford) · 2020 · PMID 30412238 · NCT00265083

Arthritis, Psoriatic (17)

  • Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.
    Trials · 2025 · PMID 40102973 · NCT05669833
  • Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Arthritis Res Ther · 2022 · PMID 35313978 · NCT02181673
  • The relationship between the nail and systemic enthesitis in psoriatic arthritis.
    Rheumatol Adv Pract · 2022 · PMID 34888436 · NCT03955861
  • Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Arthritis Res Ther · 2021 · PMID 32143685 · NCT02181673
  • GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Ann Rheum Dis · 2020 · PMID 32193187 · NCT02065713

Chronic recurrent multifocal osteomyelitis (7)

  • Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis.
    J Rheumatol · 2023 · PMID 37399459 · NCT04725422
  • The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry.
    Rheumatology (Oxford) · 2022 · PMID 29596638 · NCT04725422
  • Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions.
    Arthritis Care Res (Hoboken) · 2019 · PMID 29112802 · NCT04725422
  • Disease burden and social impact of pediatric chronic nonbacterial osteomyelitis from the patient and family perspective.
    Pediatr Rheumatol Online J · 2019 · PMID 30547806 · NCT04725422
  • Chronic Nonbacterial Osteomyelitis and Chronic Recurrent Multifocal Osteomyelitis in Children.
    Pediatr Clin North Am · 2018 · PMID 30031498 · NCT04725422

Axial Spondyloarthritis (4)

  • Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
    Adv Ther · 2023 · PMID 36995469 · NCT02437162
  • Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model.
    Ann Rheum Dis · 2013 · PMID 23139267 · NCT03270501
  • Spondyloarthritis.
    Lancet · 2011 · PMID 21684383 · NCT03270501
  • HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis.
    J Rheumatol · 1985 · PMID 3875721 · NCT03270501

Publications by journal

Trial-results highlights

For rheumatoid arthritis, a study (NCT00264537) measured the change from baseline in the total Van Der Heijde Modified Sharp (vdH-S) score at Week 52. The combined Golimumab + Methotrexate group showed a mean change of 0.41 scores. In comparison, the Placebo + Methotrexate group had a mean change of 1.37 scores, the Golimumab 100 mg + Placebo group had 1.25 scores, the Golimumab 50 mg + Methotrexate group had 0.74 scores, and the Golimumab 100 mg + Methotrexate group had 0.07 scores. In the same study, the number of participants who achieved an American College of Rheumatology (ACR) 50 response at Week 24 included 122 participants in the combined Golimumab + Methotrexate group, 47 in the Placebo + Methotrexate group, 52 in the Golimumab 100 mg + Placebo group, 64 in the Golimumab 50 mg + Methotrexate group, and 58 in the Golimumab 100 mg + Methotrexate group. Another rheumatoid arthritis study (NCT00264550, GO-FORWARD) reported a median change from baseline in Health Assessment Questionnaire (HAQ) score at Week 24 of 0.4375 units for the combined Golimumab + Methotrexate group, compared to 0.1250 units for Placebo + Methotrexate, 0.1250 units for Golimumab 100 mg + Placebo, 0.3750 units for Golimumab 50 mg + Methotrexate, and 0.5000 units for Golimumab 100 mg + Methotrexate. For ACR 20 response at Week 14 in NCT00264550, the combined Golimumab + Methotrexate group had 99 participants, while the Placebo + Methotrexate group had 44 participants, the Golimumab 100 mg + Placebo group had 59 participants, the Golimumab 50 mg + Methotrexate group had 49 participants, and the Golimumab 100 mg + Methotrexate group had 50 participants. In a separate rheumatoid arthritis study (NCT00299546), ACR 20 response at Week 14 was achieved by 105 participants in the combined Golimumab group, 27 participants in the Placebo group, 51 participants in the Golimumab 50 mg group, and 54 participants in the Golimumab 100 mg group.

For ankylosing spondylitis, a study (NCT00265083) found that at Week 14, 166 participants in the combined Golimumab 50 mg and 100 mg groups achieved an Assessment in Ankylosing Spondylitis 20 (ASAS 20) response. In comparison, 17 participants in the Placebo group achieved this response, 82 participants in the Golimumab 50 mg group, and 84 participants in the Golimumab 100 mg group.

In psoriatic arthritis, the GO-REVEAL study (NCT00265096) reported that at Week 14, 140 participants in the combined Golimumab 50 mg and 100 mg groups achieved an ACR 20 response. This compared to 10 participants in the Placebo group, 74 participants in the Golimumab 50 mg group, and 66 participants in the Golimumab 100 mg group. The same study also assessed the change from baseline in total radiographic scores of the hands and feet at Week 24. The combined Golimumab 50 mg and 100 mg groups showed a mean change of -0.09 scores. The Placebo group had a mean change of 0.27 scores, the Golimumab 50 mg group had -0.16 scores, and the Golimumab 100 mg group had -0.02 scores. All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Golimumab publications (264)

2026 (3 papers)

  1. Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study.
    Turner D, Lomax KG, Veereman G, et al. · Inflamm Bowel Dis · 2026 · Derived
    PubMed: PMID 41503939 · NCT03596645 (PURSUIT 2) · Colitis, Ulcerative
  2. Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study.
    Luque M, Zhelyazkova K, Vashishta L, et al. · BioDrugs · 2026 · Derived
    PubMed: PMID 41182658 · NCT05842213 (ALVOFLEX) · Arthritis, Rheumatoid
  3. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
    Chaparro M, Barreiro-de Acosta M, Benítez JM, et al. · Ther Adv Gastroenterol · 2026 · Background
    PubMed: PMID 31205485 · NCT05313620 · Colitis, Ulcerative

2025 (3 papers)

  1. Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.
    Ogdie A, Reddy SM, Gillespie SH, et al. · Trials · 2025 · Derived
    PubMed: PMID 40102973 · NCT05669833 (EVOLUTION) · Arthritis, Psoriatic
  2. Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study.
    Bessette L, Boulos P, Arendse R, et al. · Patient Prefer Adherence · 2025 · Derived
    PubMed: PMID 40585577 · NCT03729349 (GO FAR) · Arthritis, Rheumatoid
  3. New Interleukin-23 Antagonists' Use in Crohn's Disease.
    Biskup L, Semeradt J, Rogowska J, et al. · Pharmaceuticals (Basel) · 2025 · Background
    PubMed: PMID 40283885 · NCT07495644 · Colitis, Ulcerative

2024 (2 papers)

  1. Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions.
    Shao J, Vetter M, Vermeulen A, et al. · Clin Pharmacol Ther · 2024 · Derived
    PubMed: PMID 38488354 · NCT03662542 (VEGA) · Colitis, Ulcerative
  2. Immunogenicity of biologics in inflammatory bowel disease.
    Vermeire S, Gils A, Accossato P, et al. · Ther Adv Gastroenterol · 2024 · Background
    PubMed: PMID 29383030 · NCT07495644 · Colitis, Ulcerative

2023 (10 papers)

  1. Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK).
    Weinstein CLJ, Sliwinska-Stanczyk P, Hála T, et al. · Rheumatology (Oxford) · 2023 · Trial result
    PubMed: PMID 36919768 · NCT03253796 · Spondylarthritis
  2. Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies.
    Weinstein CLJ, Meehan AG, Govoni M, et al. · Crohns Colitis 360 · 2023 · Derived
    PubMed: PMID 37691729 · NCT00488631 · Colitis, Ulcerative
  3. Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
    Lord SM, Bahnson HT, Greenbaum CJ, et al. · PLoS One · 2023 · Derived
    PubMed: PMID 38096190 · NCT03632759 · Diabetes Mellitus, Type 1
  4. Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial.
    Krabbe S, Renson T, Jans L, et al. · Rheumatology (Oxford) · 2023 · Derived
    PubMed: PMID 36200875 · NCT01426815 (CRESPA)
  5. Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
    Kavanaugh A, Baraliakos X, Gao S, et al. · Adv Ther · 2023 · Derived
    PubMed: PMID 36995469 · NCT02437162 · Axial Spondyloarthritis
  6. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
    Feagan BG, Sands BE, Sandborn WJ, et al. · Lancet Gastroenterol Hepatol · 2023 · Derived
    PubMed: PMID 36738762 · NCT03662542 (VEGA) · Colitis, Ulcerative
  7. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
    Deodhar A, Shiff NJ, Gong C, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 37322274 · NCT02186873 · Spondylitis, Ankylosing
  8. Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study.
    Broadwell A, Schechtman J, Conaway D, et al. · BMC Rheumatol · 2023 · Derived
    PubMed: PMID 36973741 · NCT02728934 (AWARE) · Arthritis, Rheumatoid
  9. Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study.
    Bingham CO, Black S, Shiff NJ, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 36820983 · NCT02728934 (AWARE) · Arthritis, Rheumatoid
  10. Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis.
    Wu EY, Oliver M, Scheck J, et al. · J Rheumatol · 2023 · Background
    PubMed: PMID 37399459 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis

2022 (14 papers)

  1. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.
    Magro F, Lopes S, Silva M, et al. · Ther Adv Gastroenterol · 2022 · Trial result
    PubMed: PMID 31516554 · NCT02318667 (EVOLUTION) · Colitis, Ulcerative
  2. Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension.
    van der Heijde D, Dougados M, Maksymowych WP, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 33878154 · NCT01453725 (GO-AHEAD) · Spondylitis, Ankylosing
  3. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).
    Probert CS, Sebastian S, Gaya DR, et al. · BMJ Open Gastroenterol · 2022 · Derived
    PubMed: PMID 30002864 · NCT02092285 (GO-COLITIS) · Colitis, Ulcerative
  4. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
    Perrig K, Krupka N, Jordi SBU, et al. · Ther Adv Gastroenterol · 2022 · Derived
    PubMed: PMID 35154389 · NCT00488631 · Colitis, Ulcerative
  5. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations.
    Leu JH, Shiff NJ, Clark M, et al. · Paediatr Drugs · 2022 · Derived
    PubMed: PMID 36171515 · NCT02277444 (GO-VIVA) · Arthritis, Juvenile
  6. Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Lee JB, Broadwell A, Fan Y, et al. · Clin Ther · 2022 · Derived
    PubMed: PMID 35183373 · NCT00973479 · Arthritis, Rheumatoid
  7. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME, Deodhar A, Schwartzman S, et al. · Arthritis Res Ther · 2022 · Derived
    PubMed: PMID 35313978 · NCT02181673 · Arthritis, Psoriatic
  8. PAID study design on the role of PKC activation in immune/inflammation-related depression: a randomised placebo-controlled trial protocol.
    Guo X, Mao R, Cui L, et al. · Gen Psychiatr · 2022 · Derived
    PubMed: PMID 33912799 · NCT04156425 · Depressive Disorder, Major
  9. The relationship between the nail and systemic enthesitis in psoriatic arthritis.
    Elliott A, Pendleton A, Wright G, et al. · Rheumatol Adv Pract · 2022 · Derived
    PubMed: PMID 34888436 · NCT03955861 · Arthritis, Psoriatic
  10. Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.
    Deodhar AA, Shiff NJ, Gong C, et al. · J Clin Rheumatol · 2022 · Derived
    PubMed: PMID 35653615 · NCT02186873 · Spondylitis, Ankylosing
  11. Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study.
    Curtis JR, Chakravarty SD, Black S, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 34417735 · NCT02728934 (AWARE) · Arthritis, Rheumatoid
  12. Adjunct Thrombolysis Enhances Brain Reperfusion following Successful Thrombectomy.
    Laredo C, Rodríguez A, Oleaga L, et al. · Ann Neurol · 2022 · Background
    PubMed: PMID 36054449 · NCT07495644 · Colitis, Ulcerative
  13. The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry.
    Girschick H, Finetti M, Orlando F, et al. · Rheumatology (Oxford) · 2022 · Background
    PubMed: PMID 29596638 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  14. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles.
    Fuchs F, Schillinger D, Atreya R, et al. · Front Immunol · 2022 · Background
    PubMed: PMID 28717358 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2021 (10 papers)

  1. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.
    Stefanovic S, Detrez I, Compernolle G, et al. · Eur J Gastroenterol Hepatol · 2021 · Trial result
    PubMed: PMID 32804854 · NCT04156984 · Colitis, Ulcerative
  2. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
    Ruperto N, Brunner HI, Pacheco-Tena C, et al. · Rheumatology (Oxford) · 2021 · Derived
    PubMed: PMID 33493312 · NCT02277444 (GO-VIVA) · Arthritis, Juvenile
  3. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
    Reveille JD, Hwang MC, Danve A, et al. · Clin Rheumatol · 2021 · Derived
    PubMed: PMID 32926247 · NCT02186873 · Spondylitis, Ankylosing
  4. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P, Husni ME, Kafka S, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 32143685 · NCT02181673 · Arthritis, Psoriatic
  5. TNFi-induced sustained clinical remission in peripheral spondyloarthritis patients cannot be maintained with a step-down strategy based on methotrexate.
    Carron P, De Craemer AS, Renson T, et al. · Rheumatology (Oxford) · 2021 · Derived
    PubMed: PMID 33471112 · NCT01426815 (CRESPA)
  6. An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation.
    Gurbel PA, Bliden K, Barnett SD, et al. · J Cardiovasc Pharmacol Ther · 2021 · Background
    PubMed: PMID 32672062 · NCT05313620 · Colitis, Ulcerative
  7. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP, Chaparro M · J Crohns Colitis · 2021 · Background
    PubMed: PMID 31777929 · NCT05313620 · Colitis, Ulcerative
  8. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel.
    Cirillo P, Taglialatela V, Pellegrino G, et al. · J Thromb Thrombolysis · 2021 · Background
    PubMed: PMID 32335777 · NCT05313620 · Colitis, Ulcerative
  9. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
    Chaparro M, Garre A, Mesonero F, et al. · J Crohns Colitis · 2021 · Background
    PubMed: PMID 32969471 · NCT05313620 · Colitis, Ulcerative
  10. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S, Vadstrup K, Borsi A, et al. · Scand J Gastroenterol · 2021 · Background
    PubMed: PMID 32116064 · NCT07495644 · Colitis, Ulcerative

2020 (26 papers)

  1. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
    Magro F, Lopes S, Silva M, et al. · J Crohns Colitis · 2020 · Trial result
    PubMed: PMID 30989180 · NCT02318667 (EVOLUTION) · Colitis, Ulcerative
  2. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E, Alves P, Rodrigues AM, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 32193187 · NCT02065713 (GO-DACT) · Arthritis, Psoriatic
  3. Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.
    Tesser J, Kafka S, DeHoratius RJ, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31429794 · NCT00973479 · Arthritis, Rheumatoid
  4. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.
    Samaan MA, Cunningham G, Tamilarasan AG, et al. · Aliment Pharmacol Ther · 2020 · Derived
    PubMed: PMID 32506695 · NCT03124121 (GO-LEVEL) · Colitis, Ulcerative
  5. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
    Reinisch W, Gibson PR, Sandborn WJ, et al. · J Crohns Colitis · 2020 · Derived
    PubMed: PMID 29917070 · NCT00488631 · Colitis, Ulcerative
  6. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
    Quattrin T, Haller MJ, Steck AK, et al. · N Engl J Med · 2020 · Derived
    PubMed: PMID 33207093 · NCT02846545 (T1GER) · Diabetes Mellitus, Type 1
  7. Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis.
    Plein S, Erhayiem B, Fent G, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 32859608 · NCT01295151 (SWITCH) · Arthritis, Rheumatoid
  8. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
    Philip G, Cornillie F, Adedokun JO, et al. · J Crohns Colitis · 2020 · Derived
    PubMed: PMID 30847474 · NCT00488631 · Colitis, Ulcerative
  9. A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials.
    Li K, Strauss R, Marano C, et al. · J Crohns Colitis · 2020 · Derived
    PubMed: PMID 30721964 · NCT01988961 · Colitis, Ulcerative
  10. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Leu JH, Adedokun OJ, Gargano C, et al. · Rheumatology (Oxford) · 2020 · Derived
    PubMed: PMID 30412238 · NCT00265083 · Spondylitis, Ankylosing
  11. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
    Kavanaugh A, Husni ME, Harrison DD, et al. · J Rheumatol · 2020 · Derived
    PubMed: PMID 30770519 · NCT02181673 · Arthritis, Psoriatic
  12. Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.
    Husni ME, Kavanaugh A, Murphy F, et al. · Arthritis Care Res (Hoboken) · 2020 · Derived
    PubMed: PMID 30980514 · NCT02181673 · Arthritis, Psoriatic
  13. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.
    de Jong HMY, van Mens LJJ, Nurmohamed MT, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31521192 · NCT01871649 · Arthritis, Psoriatic
  14. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ, Xu Z, Liao S, et al. · Clin Ther · 2020 · Derived
    PubMed: PMID 31982148 · NCT00487539 · Colitis, Ulcerative
  15. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K, Nogami K, Ogiwara K, et al. · Int J Hematol · 2020 · Background
    PubMed: PMID 31254165 · NCT05313620 · Colitis, Ulcerative
  16. Effects of fibrinogen supplementation on clot formation in blood samples from cardiac surgery patients before and after tranexamic acid administration.
    Waldén K, Shams Hakimi C, Jeppsson A, et al. · Transfus Med · 2020 · Background
    PubMed: PMID 31115109 · NCT05313620 · Colitis, Ulcerative
  17. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.
    van Bentum RE, Heslinga SC, Nurmohamed MT, et al. · J Rheumatol · 2020 · Background
    PubMed: PMID 30385705 · NCT01668004 (GO-EASY) · Spondylitis, Ankylosing
  18. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
    Sandborn WJ, Panés J, Sands BE, et al. · Aliment Pharmacol Ther · 2020 · Background
    PubMed: PMID 31599001 · NCT05313620 · Colitis, Ulcerative
  19. Management of venous thromboembolism: an update.
    Piran S, Schulman S · Thromb J · 2020 · Background
    PubMed: PMID 27766049 · NCT05313620 · Colitis, Ulcerative
  20. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A, Desai RJ, Solomon DH, et al. · Ann Rheum Dis · 2020 · Background
    PubMed: PMID 30679153 · NCT04115423 · Arthritis, Rheumatoid
  21. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas.
    Patel-Hett S, Martin EJ, Mohammed BM, et al. · Haemophilia · 2020 · Background
    PubMed: PMID 31336410 · NCT05313620 · Colitis, Ulcerative
  22. Hypercoagulability After Resection of Thoracic Malignancy: A Prospective Evaluation.
    Mulder MB, Proctor KG, Valle EJ, et al. · World J Surg · 2020 · Background
    PubMed: PMID 31407092 · NCT05313620 · Colitis, Ulcerative
  23. Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
    Meah MN, Raftis J, Wilson SJ, et al. · Arterioscler Thromb Vasc Biol · 2020 · Background
    PubMed: PMID 32907366 · NCT05313620 · Colitis, Ulcerative
  24. New insights and long-term safety of tocilizumab in rheumatoid arthritis.
    Jones G, Panova E · Ther Adv Musculoskelet Dis · 2020 · Background
    PubMed: PMID 30327685 · NCT04115423 · Arthritis, Rheumatoid
  25. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    GBD 2017 Inflammatory Bowel Disease Collaborators · Lancet Gastroenterol Hepatol · 2020 · Background
    PubMed: PMID 31648971 · NCT07495644 · Colitis, Ulcerative
  26. The Effect of Immunosuppression on Coagulation After Liver Transplantation.
    Bedreli S, Straub K, Achterfeld A, et al. · Liver Transpl · 2020 · Background
    PubMed: PMID 31021493 · NCT05313620 · Colitis, Ulcerative

2019 (18 papers)

  1. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
    van Mens LJJ, de Jong HM, Fluri I, et al. · Ann Rheum Dis · 2019 · Derived
    PubMed: PMID 30808625 · NCT01871649 · Arthritis, Psoriatic
  2. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    Hibi T, Imai Y, Senoo A, et al. · J Gastroenterol · 2019 · Derived
    PubMed: PMID 28324167 · NCT01863771 · Colitis, Ulcerative
  3. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
    Deodhar A, Reveille JD, Harrison DD, et al. · J Rheumatol · 2019 · Derived
    PubMed: PMID 29247154 · NCT02186873 · Spondylitis, Ankylosing
  4. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
    Deodhar A, Gensler LS, Sieper J, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 30225992 · NCT02438787 · Spondylitis, Ankylosing
  5. High Rate of Drug-Free Remission After Induction Therapy With Golimumab in Early Peripheral Spondyloarthritis.
    Carron P, Varkas G, Renson T, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 29806090 · NCT01426815 (CRESPA)
  6. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S, Everett CC, Naraghi K, et al. · Health Technol Assess · 2019 · Derived
    PubMed: PMID 29900829 · NCT01295151 (SWITCH) · Arthritis, Rheumatoid
  7. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
    Bossuyt P, Baert F, D'Heygere F, et al. · Inflamm Bowel Dis · 2019 · Derived
    PubMed: PMID 29920582 · NCT02155335 (SMART) · Colitis, Ulcerative
  8. Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions.
    Zhao Y, Wu EY, Oliver MS, et al. · Arthritis Care Res (Hoboken) · 2019 · Background
    PubMed: PMID 29112802 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  9. Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension.
    Vrigkou E, Tsangaris I, Bonovas S, et al. · Platelets · 2019 · Background
    PubMed: PMID 30047809 · NCT05313620 · Colitis, Ulcerative
  10. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
    van der Heijde D, Baraliakos X, Gensler LS, et al. · Lancet · 2019 · Background
    PubMed: PMID 30360970 · NCT05313620 · Colitis, Ulcerative
  11. Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.
    Stikvoort A, Chen Y, Rådestad E, et al. · Front Immunol · 2019 · Background
    PubMed: PMID 28674539 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  12. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE, Sandborn WJ, Panaccione R, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31553833 · NCT05313620 · Colitis, Ulcerative
  13. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
    Sands BE, Sandborn WJ, Feagan BG, et al. · J Crohns Colitis · 2019 · Background
    PubMed: PMID 29917064 · NCT05313620 · Colitis, Ulcerative
  14. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI, Subesinghe S, Hyrich KL, et al. · Ann Rheum Dis · 2019 · Background
    PubMed: PMID 29592917 · NCT04115423 · Arthritis, Rheumatoid
  15. Disease burden and social impact of pediatric chronic nonbacterial osteomyelitis from the patient and family perspective.
    Oliver M, Lee TC, Halpern-Felsher B, et al. · Pediatr Rheumatol Online J · 2019 · Background
    PubMed: PMID 30547806 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  16. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
    Grøn KL, Arkema EV, Glintborg B, et al. · Ann Rheum Dis · 2019 · Background
    PubMed: PMID 30612115 · NCT04115423 · Arthritis, Rheumatoid
  17. Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.
    Danese S, Allez M, van Bodegraven AA, et al. · Dig Dis · 2019 · Background
    PubMed: PMID 30726845 · NCT05313620 · Colitis, Ulcerative
  18. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M, Garre A, Ricart E, et al. · Aliment Pharmacol Ther · 2019 · Background
    PubMed: PMID 30281832 · NCT05313620 · Colitis, Ulcerative

2018 (22 papers)

  1. Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial.
    Proft F, Muche B, Listing J, et al. · BMJ Open · 2018 · Trial result
    PubMed: PMID 28601821 · NCT02758782 (CONSUL) · Spondylitis, Ankylosing
  2. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
    Telesco SE, Brodmerkel C, Zhang H, et al. · Gastroenterology · 2018 · Derived
    PubMed: PMID 29981298 · NCT01988961 · Colitis, Ulcerative
  3. Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies.
    Standish KA, Huang CC, Curran ME, et al. · Arthritis Res Ther · 2018 · Derived
    PubMed: PMID 28494788 · NCT00973479 · Arthritis, Rheumatoid
  4. Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study.
    Durez P, Vanthuyne M, Soyfoo MS, et al. · Acta Clin Belg · 2018 · Derived
    PubMed: PMID 28431485 · NCT00975130 (GO-MORE) · Arthritis, Rheumatoid
  5. Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.
    Dehoratius RJ, Brent LH, Curtis JR, et al. · Patient · 2018 · Derived
    PubMed: PMID 29427176 · NCT01004432 · Arthritis, Rheumatoid
  6. Chronic Nonbacterial Osteomyelitis and Chronic Recurrent Multifocal Osteomyelitis in Children.
    Zhao Y, Ferguson PJ · Pediatr Clin North Am · 2018 · Background
    PubMed: PMID 30031498 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  7. Ulcerative colitis.
    Ungaro R, Mehandru S, Allen PB, et al. · Lancet · 2018 · Background
    PubMed: PMID 27914657 · NCT05313620 · Colitis, Ulcerative
  8. Endoscopy in inflammatory bowel disease: advances in disease management.
    Scoville EA, Schwartz DA · Gastrointest Endosc · 2018 · Background
    PubMed: PMID 28886962 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  9. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Scott IC, Hider SL, Scott DL, et al. · Drug Saf · 2018 · Background
    PubMed: PMID 29500799 · NCT05313620 · Colitis, Ulcerative
  10. Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.
    Planell N, Masamunt MC, Leal RF, et al. · J Crohns Colitis · 2018 · Background
    PubMed: PMID 28981629 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  11. Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease.
    Park SH, Aniwan S, Loftus EV, et al. · Curr Opin Pharmacol · 2018 · Background
    PubMed: PMID 28992449 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  12. Evaluation of hypercoagulability with rotational thromboelastometry in children with iron deficiency anemia.
    Özdemir ZC, Düzenli Kar Y, Gündüz E, et al. · Hematology · 2018 · Background
    PubMed: PMID 29544395 · NCT05313620 · Colitis, Ulcerative
  13. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
    Ng SC, Shi HY, Hamidi N, et al. · Lancet · 2018 · Background
    PubMed: PMID 29050646 · NCT05313620 · Colitis, Ulcerative
  14. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
    Mesa RA, Vannucchi AM, Mead A, et al. · Lancet Haematol · 2018 · Background
    PubMed: PMID 28336242 · NCT05313620 · Colitis, Ulcerative
  15. Can We Predict the Efficacy of Anti-TNF-α Agents?
    Lopetuso LR, Gerardi V, Papa V, et al. · Int J Mol Sci · 2018 · Background
    PubMed: PMID 28906475 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  16. Effect of Albumin in Combination With Mannitol on Whole-blood Coagulation In Vitro Assessed by Thromboelastometry.
    Lillemäe K, Laine AT, Schramko A, et al. · J Neurosurg Anesthesiol · 2018 · Background
    PubMed: PMID 28498140 · NCT05313620 · Colitis, Ulcerative
  17. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
    Hindryckx P, Vande Casteele N, Novak G, et al. · J Crohns Colitis · 2018 · Background
    PubMed: PMID 28961959 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  18. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
    Hassan EA, Ramadan HK, Ismael AA, et al. · Saudi J Gastroenterol · 2018 · Background
    PubMed: PMID 28721978 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  19. Tranexamic acid is associated with selective increase in inflammatory markers following total knee arthroplasty (TKA): a pilot study.
    Grant AL, Letson HL, Morris JL, et al. · J Orthop Surg Res · 2018 · Background
    PubMed: PMID 29914535 · NCT05313620 · Colitis, Ulcerative
  20. Ustekinumab to treat Crohn's disease.
    Gisbert JP, Chaparro M · Gastroenterol Hepatol · 2018 · Background
    PubMed: PMID 29042094 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  21. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease.
    Feng T, Chen B, Li L, et al. · Inflamm Bowel Dis · 2018 · Background
    PubMed: PMID 28644181 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  22. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E, Gisbert JP · Gastroenterol Hepatol · 2018 · Background
    PubMed: PMID 26948838 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2017 (26 papers)

  1. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC, Zwillich SH, Jansen JP, et al. · Clin Ther · 2017 · Derived
    PubMed: PMID 27889300 · NCT00299546 · Arthritis, Rheumatoid
  2. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
    Mack ME, Hsia E, Aletaha D, et al. · Arthritis Rheumatol · 2017 · Derived
    PubMed: PMID 27696724 · NCT00264550 (GO-FORWARD) · Arthritis, Rheumatoid
  3. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Kay J, Fleischmann R, Keystone E, et al. · J Rheumatol · 2017 · Derived
    PubMed: PMID 27803138 · NCT00265096 (GO-REVEAL) · Arthritis, Psoriatic
  4. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
    Kavanaugh A, Husni ME, Harrison DD, et al. · Arthritis Rheumatol · 2017 · Derived
    PubMed: PMID 28805045 · NCT02181673 · Arthritis, Psoriatic
  5. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
    Inman RD, Baraliakos X, Hermann KA, et al. · Arthritis Res Ther · 2017 · Derived
    PubMed: PMID 28031053 · NCT00265083 · Spondylitis, Ankylosing
  6. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
    Huffstutter JE, Kafka S, Brent LH, et al. · Curr Med Res Opin · 2017 · Derived
    PubMed: PMID 28035867 · NCT01004432 · Arthritis, Rheumatoid
  7. Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis.
    George MD, Østergaard M, Conaghan PG, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 28606966 · NCT00264550 (GO-FORWARD) · Arthritis, Rheumatoid
  8. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study.
    Carron P, Varkas G, Cypers H, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 28213565 · NCT01426815 (CRESPA)
  9. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
    Brunner HI, Ruperto N, Tzaribachev N, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 28507219 · NCT01230827 · Arthritis, Juvenile
  10. Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
    Braun J, Baraliakos X, Hermann KG, et al. · J Rheumatol · 2017 · Derived
    PubMed: PMID 26932345 · NCT00265083 · Spondylitis, Ankylosing
  11. Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
    Braun J, Baraliakos X, Hermann KG, et al. · J Rheumatol · 2017 · Derived
    PubMed: PMID 27422890 · NCT00265083 · Spondylitis, Ankylosing
  12. Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis.
    Baker JF, Conaghan PG, Emery P, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27432355 · NCT00264537 · Arthritis, Rheumatoid
  13. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression.
    Aletaha D, Alasti F, Smolen JS, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27457512 · NCT00265096 (GO-REVEAL) · Arthritis, Psoriatic
  14. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials.
    Vuitton L, Marteau P, Sandborn WJ, et al. · Gut · 2017 · Background
    PubMed: PMID 26353983 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  15. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF.
    Viazis N, Giakoumis M, Bamias G, et al. · Dig Liver Dis · 2017 · Background
    PubMed: PMID 27866814 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  16. Mass Cytometry of the Human Mucosal Immune System Identifies Tissue- and Disease-Associated Immune Subsets.
    van Unen V, Li N, Molendijk I, et al. · Immunity · 2017 · Background
    PubMed: PMID 27178470 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  17. Mass Cytometry: Single Cells, Many Features.
    Spitzer MH, Nolan GP · Cell · 2017 · Background
    PubMed: PMID 27153492 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  18. Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.
    Singh JA · Curr Rheumatol Rep · 2017 · Background
    PubMed: PMID 27613285 · NCT04115423 · Arthritis, Rheumatoid
  19. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA, Hossain A, Tanjong Ghogomu E, et al. · Cochrane Database Syst Rev · 2017 · Background
    PubMed: PMID 28282491 · NCT04115423 · Arthritis, Rheumatoid
  20. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S, Sepriano A, Chatzidionysiou K, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 28298374 · NCT04115423 · Arthritis, Rheumatoid
  21. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.
    Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L, et al. · Expert Rev Gastroenterol Hepatol · 2017 · Background
    PubMed: PMID 27043489 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  22. Effects of preoperative aspirin on perioperative platelet activation and dysfunction in patients undergoing off-pump coronary artery bypass graft surgery: A prospective randomized study.
    Lee J, Jung CW, Jeon Y, et al. · PLoS One · 2017 · Background
    PubMed: PMID 28715503 · NCT05313620 · Colitis, Ulcerative
  23. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Gisbert JP, Marín AC, Chaparro M, et al. · Am J Gastroenterol · 2017 · Background
    PubMed: PMID 27002797 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  24. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
    Arbelaiz A, Azkargorta M, Krawczyk M, et al. · Hepatology · 2017 · Background
    PubMed: PMID 28555885 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  25. Procoagulant profile in patients with immune thrombocytopenia.
    Álvarez-Román MT, Fernández-Bello I, Jiménez-Yuste V, et al. · Br J Haematol · 2017 · Background
    PubMed: PMID 27766635 · NCT05313620 · Colitis, Ulcerative
  26. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ, Xu Z, Marano CW, et al. · J Crohns Colitis · 2017 · Background
    PubMed: PMID 27440869 · NCT03669029 · Colitis, Ulcerative

2016 (22 papers)

  1. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
    Sieper J, van der Heijde D, Dougados M, et al. · Arthritis Rheumatol · 2016 · Trial result
    PubMed: PMID 26139307 · NCT01453725 (GO-AHEAD) · Spondylitis, Ankylosing
  2. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.
    Smolen JS, Kay J, Doyle M, et al. · Arthritis Res Ther · 2016 · Derived
    PubMed: PMID 25627338 · NCT00299546 · Arthritis, Rheumatoid
  3. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
    Rutgeerts P, Feagan BG, Marano CW, et al. · Aliment Pharmacol Ther · 2016 · Derived
    PubMed: PMID 26119226 · NCT00488774 · Colitis, Ulcerative
  4. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.
    Kavanaugh A, van der Heijde D, Beutler A, et al. · Arthritis Care Res (Hoboken) · 2016 · Derived
    PubMed: PMID 25779603 · NCT00265096 (GO-REVEAL) · Arthritis, Psoriatic
  5. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO, Mendelsohn AM, Kim L, et al. · Arthritis Care Res (Hoboken) · 2016 · Derived
    PubMed: PMID 25623393 · NCT00973479 · Arthritis, Rheumatoid
  6. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H, Xie F, Delzell E, et al. · Arthritis Rheumatol · 2016 · Background
    PubMed: PMID 26315675 · NCT04115423 · Arthritis, Rheumatoid
  7. The epidemiology and risk factors of inflammatory bowel disease.
    Ye Y, Pang Z, Chen W, et al. · Int J Clin Exp Med · 2016 · Background
    PubMed: PMID 26885239 · NCT05313620 · Colitis, Ulcerative
  8. Whole-body Magnetic Resonance Imaging in Chronic Recurrent Multifocal Osteomyelitis: Clinical Longterm Assessment May Underestimate Activity.
    Voit AM, Arnoldi AP, Douis H, et al. · J Rheumatol · 2016 · Background
    PubMed: PMID 25979713 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  9. Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study.
    Tsantes AE, Kyriakou E, Ikonomidis I, et al. · Medicine (Baltimore) · 2016 · Background
    PubMed: PMID 27057830 · NCT05313620 · Colitis, Ulcerative
  10. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
    Tew GW, Hackney JA, Gibbons D, et al. · Gastroenterology · 2016 · Background
    PubMed: PMID 26522261 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  11. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.
    Shah SC, Colombel JF, Sands BE, et al. · Aliment Pharmacol Ther · 2016 · Background
    PubMed: PMID 26607562 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  12. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
    Sakai R, Cho SK, Nanki T, et al. · Arthritis Res Ther · 2016 · Background
    PubMed: PMID 25880658 · NCT04115423 · Arthritis, Rheumatoid
  13. Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.
    Niewiadomski O, Studd C, Hair C, et al. · J Crohns Colitis · 2016 · Background
    PubMed: PMID 26129692 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  14. Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.
    Nair N, Mei HE, Chen SY, et al. · Arthritis Res Ther · 2016 · Background
    PubMed: PMID 25981462 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  15. The Role of Platelets in Venous Thromboembolism.
    Montoro-García S, Schindewolf M, Stanford S, et al. · Semin Thromb Hemost · 2016 · Background
    PubMed: PMID 26926584 · NCT05313620 · Colitis, Ulcerative
  16. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
    Kopylov U, Seidman E · Ther Adv Gastroenterol · 2016 · Background
    PubMed: PMID 27366220 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  17. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
    Jin Y, Lin Y, Lin LJ, et al. · World J Gastroenterol · 2016 · Background
    PubMed: PMID 26034371 · NCT07495644 · Colitis, Ulcerative
  18. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys.
    Gordon JP, McEwan PC, Maguire A, et al. · Eur J Gastroenterol Hepatol · 2016 · Background
    PubMed: PMID 25933126 · NCT05313620 · Colitis, Ulcerative
  19. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP, Domènech E · Gastroenterol Hepatol · 2016 · Background
    PubMed: PMID 25619903 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  20. Clinical recovery from surgery correlates with single-cell immune signatures.
    Gaudillière B, Fragiadakis GK, Bruggner RV, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25253674 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  21. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.
    Ding NS, Hart A, De Cruz P, et al. · Aliment Pharmacol Ther · 2016 · Background
    PubMed: PMID 26515897 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  22. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.
    Dahlén R, Magnusson MK, Bajor A, et al. · Scand J Gastroenterol · 2016 · Background
    PubMed: PMID 25877762 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2015 (18 papers)

  1. Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis.
    Schulze-Koops H, Giacomelli R, Samborski W, et al. · Clin Exp Rheumatol · 2015 · Derived
    PubMed: PMID 25664404 · NCT00975130 (GO-MORE) · Arthritis, Rheumatoid
  2. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
    Navarro Coy NC, Brown S, Bosworth A, et al. · BMC Musculoskelet Disord · 2015 · Derived
    PubMed: PMID 25539805 · NCT01295151 (SWITCH) · Arthritis, Rheumatoid
  3. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure.
    Judson MA, Mack M, Beaumont JL, et al. · Am J Respir Crit Care Med · 2015 · Derived
    PubMed: PMID 25594886 · NCT00955279 · Sarcoidosis
  4. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
    Judson MA, Baughman RP, Costabel U, et al. · Eur Respir J · 2015 · Derived
    PubMed: PMID 25034562 · NCT00955279 · Sarcoidosis
  5. Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.
    Emery P, Fleischmann RM, Hsia EC, et al. · Clin Rheumatol · 2015 · Derived
    PubMed: PMID 25005327 · NCT00264537 · Arthritis, Rheumatoid
  6. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
    Deodhar A, Braun J, Inman RD, et al. · Ann Rheum Dis · 2015 · Derived
    PubMed: PMID 25387477 · NCT00265083 · Spondylitis, Ankylosing
  7. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.
    Dasgupta B, Combe B, Louw I, et al. · Arthritis Care Res (Hoboken) · 2015 · Derived
    PubMed: PMID 24839031 · NCT00975130 (GO-MORE) · Arthritis, Rheumatoid
  8. Anti-TNF therapeutics for the treatment of sarcoidosis.
    Crommelin HA, Vorselaars AD, van Moorsel CH, et al. · Immunotherapy · 2015 · Derived
    PubMed: PMID 25428650 · NCT00955279 · Sarcoidosis
  9. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO, Weinblatt M, Han C, et al. · J Rheumatol · 2015 · Derived
    PubMed: PMID 24786931 · NCT00973479 · Arthritis, Rheumatoid
  10. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
    Peyrin-Biroulet L, Sandborn W, Sands BE, et al. · Am J Gastroenterol · 2015 · Background
    PubMed: PMID 26303131 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  11. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.
    Khanna R, Bouguen G, Feagan BG, et al. · Inflamm Bowel Dis · 2015 · Background
    PubMed: PMID 25029615 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  12. Thrombosis in inflammatory bowel diseases: what's the link?
    Giannotta M, Tapete G, Emmi G, et al. · Thromb J · 2015 · Background
    PubMed: PMID 25866483 · NCT05313620 · Colitis, Ulcerative
  13. Towards personalized care in IBD.
    Gerich ME, McGovern DP · Nat Rev Gastroenterol Hepatol · 2015 · Background
    PubMed: PMID 24345887 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  14. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages.
    Fergusson JR, Smith KE, Fleming VM, et al. · Cell Rep · 2015 · Background
    PubMed: PMID 25437561 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  15. Physiological intermolecular modification spectroscopy for the prediction of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel diseases.
    Eftekhari P, Glaubitz L, Breidert M, et al. · Dig Dis · 2015 · Background
    PubMed: PMID 24969293 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  16. Rotation thromboelastometry and the hypercoagulable state in Cushing's syndrome.
    Coelho MC, Vieira Neto L, Kasuki L, et al. · Clin Endocrinol (Oxf) · 2015 · Background
    PubMed: PMID 24815846 · NCT05313620 · Colitis, Ulcerative
  17. Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients.
    Campello E, Spiezia L, Zabeo E, et al. · Thromb Res · 2015 · Background
    PubMed: PMID 25592651 · NCT05313620 · Colitis, Ulcerative
  18. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT, Fernández Bello I, Arias-Salgado EG, et al. · Thromb Haemost · 2015 · Background
    PubMed: PMID 24500066 · NCT05313620 · Colitis, Ulcerative

2014 (18 papers)

  1. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
    Combe B, Dasgupta B, Louw I, et al. · Ann Rheum Dis · 2014 · Trial result
    PubMed: PMID 23740226 · NCT00975130 (GO-MORE) · Arthritis, Rheumatoid
  2. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
    Weinblatt ME, Westhovens R, Mendelsohn AM, et al. · Ann Rheum Dis · 2014 · Derived
    PubMed: PMID 24001888 · NCT00973479 · Arthritis, Rheumatoid
  3. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ, Feagan BG, Marano C, et al. · Gastroenterology · 2014 · Derived
    PubMed: PMID 23770005 · NCT00488631 · Colitis, Ulcerative
  4. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ, Feagan BG, Marano C, et al. · Gastroenterology · 2014 · Derived
    PubMed: PMID 23735746 · NCT00487539 · Colitis, Ulcerative
  5. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
    Keystone EC, Genovese MC, Hall S, et al. · J Rheumatol · 2014 · Derived
    PubMed: PMID 23678153 · NCT00264550 (GO-FORWARD) · Arthritis, Rheumatoid
  6. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).
    Kavanaugh A, McInnes IB, Mease P, et al. · Ann Rheum Dis · 2014 · Derived
    PubMed: PMID 24748630 · NCT00265096 (GO-REVEAL) · Arthritis, Psoriatic
  7. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab.
    Helliwell PS, Kavanaugh A · Arthritis Care Res (Hoboken) · 2014 · Derived
    PubMed: PMID 24127416 · NCT00265096 (GO-REVEAL) · Arthritis, Psoriatic
  8. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Emery P, Fleischmann RM, Doyle MK, et al. · Arthritis Care Res (Hoboken) · 2014 · Derived
    PubMed: PMID 23861303 · NCT00264537 · Arthritis, Rheumatoid
  9. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C, Huang F, Khan MA, et al. · Rheumatology (Oxford) · 2014 · Derived
    PubMed: PMID 24729398 · NCT01248793 · Spondylitis, Ankylosing
  10. Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression.
    Baker JF, Conaghan PG, Smolen JS, et al. · Arthritis Rheumatol · 2014 · Derived
    PubMed: PMID 24757132 · NCT00264550 (GO-FORWARD) · Arthritis, Rheumatoid
  11. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
    Stidham RW, Lee TC, Higgins PD, et al. · Aliment Pharmacol Ther · 2014 · Background
    PubMed: PMID 24749763 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  12. Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.
    Seeley EH, Washington MK, Caprioli RM, et al. · Proteomics Clin Appl · 2014 · Background
    PubMed: PMID 23382084 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  13. Cytokines in inflammatory bowel disease.
    Neurath MF · Nat Rev Immunol · 2014 · Background
    PubMed: PMID 24751956 · NCT07495644 · Colitis, Ulcerative
  14. Inflammatory bowel disease: an expanding global health problem.
    M'Koma AE · Clin Med Insights Gastroenterol · 2014 · Background
    PubMed: PMID 24833941 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  15. Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity.
    Fernández-Bello I, López-Longo FJ, Arias-Salgado EG, et al. · Orphanet J Rare Dis · 2014 · Background
    PubMed: PMID 23711081 · NCT05313620 · Colitis, Ulcerative
  16. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M, Salem M, Pedersen J, et al. · Pharmacol Res · 2014 · Background
    PubMed: PMID 23827161 · NCT05313620 · Colitis, Ulcerative
  17. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.
    Burisch J, Pedersen N, Čuković-Čavka S, et al. · Gut · 2014 · Background
    PubMed: PMID 23604131 · NCT05313620 · Colitis, Ulcerative
  18. Primary haemostasis: newer insights.
    Berndt MC, Metharom P, Andrews RK, et al. · Haemophilia · 2014 · Background
    PubMed: PMID 24762270 · NCT05313620 · Colitis, Ulcerative

2013 (13 papers)

  1. Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study.
    van der Heijde D, Deodhar A, Inman RD, et al. · Arthritis Care Res (Hoboken) · 2013 · Derived
    PubMed: PMID 22740380 · NCT00265083 · Spondylitis, Ankylosing
  2. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).
    van der Heijde D, Braun J, Deodhar A, et al. · Rheumatology (Oxford) · 2013 · Derived
    PubMed: PMID 23024015 · NCT00265083 · Spondylitis, Ankylosing
  3. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
    Kavanaugh A, McInnes IB, Krueger GG, et al. · Arthritis Care Res (Hoboken) · 2013 · Derived
    PubMed: PMID 23666608 · NCT00265096 (GO-REVEAL) · Arthritis, Psoriatic
  4. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial.
    Doyle MK, Rahman MU, Frederick B, et al. · Rheumatology (Oxford) · 2013 · Derived
    PubMed: PMID 23418046 · NCT01362153 · Arthritis, Rheumatoid
  5. Associations between vitamin D, disease activity, and clinical response to therapy in rheumatoid arthritis.
    Baker JF, Baker DG, Toedter G, et al. · Clin Exp Rheumatol · 2013 · Derived
    PubMed: PMID 22776409 · NCT00361335 · Arthritis, Rheumatoid
  6. Platelets in thrombosis and hemostasis: old topic with new mechanisms.
    Wang Y, Andrews M, Yang Y, et al. · Cardiovasc Hematol Disord Drug Targets · 2013 · Background
    PubMed: PMID 23030445 · NCT05313620 · Colitis, Ulcerative
  7. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model.
    Van Praet L, Van den Bosch FE, Jacques P, et al. · Ann Rheum Dis · 2013 · Background
    PubMed: PMID 23139267 · NCT03270501 (GO-GUT) · Axial Spondyloarthritis
  8. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
    Steenholdt C, Al-khalaf M, Brynskov J, et al. · Inflamm Bowel Dis · 2013 · Background
    PubMed: PMID 22344964 · NCT03669029 · Colitis, Ulcerative
  9. Ulcerative colitis.
    Ordás I, Eckmann L, Talamini M, et al. · Lancet · 2013 · Background
    PubMed: PMID 22914296 · NCT05313620 · Colitis, Ulcerative
  10. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study.
    Høivik ML, Moum B, Solberg IC, et al. · Gut · 2013 · Background
    PubMed: PMID 22717453 · NCT05313620 · Colitis, Ulcerative
  11. Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease.
    Han NY, Choi W, Park JM, et al. · J Dig Dis · 2013 · Background
    PubMed: PMID 23320753 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  12. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M, Gardner I, Gurbaxani BM, et al. · Clin Pharmacokinet · 2013 · Background
    PubMed: PMID 23299465 · NCT03669029 · Colitis, Ulcerative
  13. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.
    D'Haens G, Feagan B, Colombel JF, et al. · Gastroenterology · 2013 · Background
    PubMed: PMID 23000597 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2012 (14 papers)

  1. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y, Xu Z, Frederick B, et al. · Clin Ther · 2012 · Derived
    PubMed: PMID 22169051 · NCT01362153 · Arthritis, Rheumatoid
  2. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
    Taylor PC, Ritchlin C, Mendelsohn A, et al. · J Rheumatol · 2012 · Derived
    PubMed: PMID 22089463 · NCT00361335 · Arthritis, Rheumatoid
  3. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
    Østergaard M, Emery P, Conaghan PG, et al. · Arthritis Rheum · 2012 · Derived
    PubMed: PMID 22127693 · NCT00264537 · Arthritis, Rheumatoid
  4. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
    Kavanaugh A, van der Heijde D, McInnes IB, et al. · Arthritis Rheum · 2012 · Derived
    PubMed: PMID 22378566 · NCT00265096 (GO-REVEAL) · Arthritis, Psoriatic
  5. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC, Han C, Keystone EC, et al. · J Rheumatol · 2012 · Derived
    PubMed: PMID 22505702 · NCT00264550 (GO-FORWARD) · Arthritis, Rheumatoid
  6. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment.
    Vande Casteele N, Ballet V, Van Assche G, et al. · Gut · 2012 · Background
    PubMed: PMID 21330576 · NCT03669029 · Colitis, Ulcerative
  7. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R, Olsen T, Cui G, et al. · Scand J Gastroenterol · 2012 · Background
    PubMed: PMID 22486187 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  8. Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.
    Rieder F, Karrasch T, Ben-Horin S, et al. · J Crohns Colitis · 2012 · Background
    PubMed: PMID 22405177 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  9. Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface.
    Presley LL, Ye J, Li X, et al. · Inflamm Bowel Dis · 2012 · Background
    PubMed: PMID 21698720 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  10. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease.
    Peyrin-Biroulet L, Ferrante M, Magro F, et al. · J Crohns Colitis · 2012 · Background
    PubMed: PMID 21939925 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  11. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.
    Ordás I, Mould DR, Feagan BG, et al. · Clin Pharmacol Ther · 2012 · Background
    PubMed: PMID 22357456 · NCT03669029 · Colitis, Ulcerative
  12. Mucosal healing in inflammatory bowel diseases: a systematic review.
    Neurath MF, Travis SP · Gut · 2012 · Background
    PubMed: PMID 22842618 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  13. Extracellular matrix proteins in hemostasis and thrombosis.
    Bergmeier W, Hynes RO · Cold Spring Harb Perspect Biol · 2012 · Background
    PubMed: PMID 21937733 · NCT05313620 · Colitis, Ulcerative
  14. A deep profiler's guide to cytometry.
    Bendall SC, Nolan GP, Roederer M, et al. · Trends Immunol · 2012 · Background
    PubMed: PMID 22476049 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2011 (12 papers)

  1. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.
    Visvanathan S, Rahman MU, Keystone E, et al. · Arthritis Res Ther · 2011 · Derived
    PubMed: PMID 21083889 · NCT00264550 (GO-FORWARD) · Arthritis, Rheumatoid
  2. Predicting response to Anti-TNF Agents for the treatment of crohn's disease.
    Siegel CA, Melmed GY · Ther Adv Gastroenterol · 2011 · Background
    PubMed: PMID 21180547 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  3. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.
    Nunes T, Barreiro-de Acosta M, Nos P, et al. · J Crohns Colitis · 2011 · Background
    PubMed: PMID 21122572 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  4. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.
    M'Koma AE, Seeley EH, Washington MK, et al. · Inflamm Bowel Dis · 2011 · Background
    PubMed: PMID 20806340 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  5. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC, Sandborn WJ, Khan KJ, et al. · Am J Gastroenterol · 2011 · Background
    PubMed: PMID 21407183 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  6. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.
    Fasanmade AA, Adedokun OJ, Ford J, et al. · Eur J Clin Pharmacol · 2011 · Background
    PubMed: PMID 19756557 · NCT03669029 · Colitis, Ulcerative
  7. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA, Adedokun OJ, Blank M, et al. · Clin Ther · 2011 · Background
    PubMed: PMID 21741088 · NCT03669029 · Colitis, Ulcerative
  8. Spondyloarthritis.
    Dougados M, Baeten D · Lancet · 2011 · Background
    PubMed: PMID 21684383 · NCT03270501 (GO-GUT) · Axial Spondyloarthritis
  9. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR, Panaccione R, Higgins PD, et al. · Am J Gastroenterol · 2011 · Background
    PubMed: PMID 21045814 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  10. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF, Rutgeerts P, Reinisch W, et al. · Gastroenterology · 2011 · Background
    PubMed: PMID 21723220 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  11. Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
    Brophy DF, Martin EJ, Christian Barrett J, et al. · Haemophilia · 2011 · Background
    PubMed: PMID 21362113 · NCT05313620 · Colitis, Ulcerative
  12. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
    Arijs I, Quintens R, Van Lommel L, et al. · Inflamm Bowel Dis · 2011 · Background
    PubMed: PMID 20848504 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2010 (9 papers)

  1. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J, Ritchlin C, Mendelsohn A, et al. · Arthritis Rheum · 2010 · Derived
    PubMed: PMID 20131276 · NCT00361335 · Arthritis, Rheumatoid
  2. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial.
    Deodhar A, Braun J, Inman RD, et al. · Arthritis Care Res (Hoboken) · 2010 · Derived
    PubMed: PMID 20506403 · NCT00265083 · Spondylitis, Ankylosing
  3. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions.
    Nishimoto N, Ito K, Takagi N, et al. · Mod Rheumatol · 2010 · Background
    PubMed: PMID 20221663 · NCT04115423 · Arthritis, Rheumatoid
  4. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
    Li Z, Arijs I, De Hertogh G, et al. · Inflamm Bowel Dis · 2010 · Background
    PubMed: PMID 20196149 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  5. Risk assessment for recurrent venous thrombosis.
    Kyrle PA, Rosendaal FR, Eichinger S, et al. · Lancet · 2010 · Background
    PubMed: PMID 21131039 · NCT05313620 · Colitis, Ulcerative
  6. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.
    Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology, et al. · Am J Gastroenterol · 2010 · Background
    PubMed: PMID 20068560 · NCT05313620 · Colitis, Ulcerative
  7. Infliximab, azathioprine, or combination therapy for Crohn's disease.
    Colombel JF, Sandborn WJ, Reinisch W, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20393175 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  8. Systematic review: the costs of ulcerative colitis in Western countries.
    Cohen RD, Yu AP, Wu EQ, et al. · Aliment Pharmacol Ther · 2010 · Background
    PubMed: PMID 20064142 · NCT05313620 · Colitis, Ulcerative
  9. Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment.
    Beck C, Morbach H, Beer M, et al. · Arthritis Res Ther · 2010 · Background
    PubMed: PMID 20433730 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis

2009 (4 papers)

  1. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, et al. · Lancet · 2009 · Derived
    PubMed: PMID 19560810 · NCT00299546 · Arthritis, Rheumatoid
  2. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
    Olsen T, Goll R, Cui G, et al. · Cytokine · 2009 · Background
    PubMed: PMID 19286392 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  3. Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry.
    Nanni P, Mezzanotte L, Roda G, et al. · J Proteomics · 2009 · Background
    PubMed: PMID 19168159 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  4. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
    Arijs I, Li K, Toedter G, et al. · Gut · 2009 · Background
    PubMed: PMID 19700435 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2008 (5 papers)

  1. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Kay J, Matteson EL, Dasgupta B, et al. · Arthritis Rheum · 2008 · Derived
    PubMed: PMID 18383539 · NCT00207714 · Arthritis, Rheumatoid
  2. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
    Nanni P, Parisi D, Roda G, et al. · Rapid Commun Mass Spectrom · 2008 · Background
    PubMed: PMID 18022963 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  3. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
    Meuwis MA, Fillet M, Lutteri L, et al. · Clin Biochem · 2008 · Background
    PubMed: PMID 18489908 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  4. Triggers, targets and treatments for thrombosis.
    Mackman N · Nature · 2008 · Background
    PubMed: PMID 18288180 · NCT05313620 · Colitis, Ulcerative
  5. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram.
    Lak M, Scharling B, Blemings A, et al. · Haemophilia · 2008 · Background
    PubMed: PMID 18070065 · NCT05313620 · Colitis, Ulcerative

2007 (6 papers)

  1. Unravelling the pathogenesis of inflammatory bowel disease.
    Xavier RJ, Podolsky DK · Nature · 2007 · Background
    PubMed: PMID 17653185 · NCT07495644 · Colitis, Ulcerative
  2. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.
    Shkoda A, Werner T, Daniel H, et al. · J Proteome Res · 2007 · Background
    PubMed: PMID 17330946 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  3. Infliximab in fistulizing Crohn's disease.
    Osterman MT, Lichtenstein GR · Gastroenterol Clin North Am · 2007 · Background
    PubMed: PMID 17129814 · NCT07495644 · Colitis, Ulcerative
  4. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA, Sandborn WJ, Gassull M, et al. · Gastroenterology · 2007 · Background
    PubMed: PMID 17241860 · NCT05313620 · Colitis, Ulcerative
  5. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
    D'Haens G, Sandborn WJ, Feagan BG, et al. · Gastroenterology · 2007 · Background
    PubMed: PMID 17258735 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  6. Trends in hospitalization rates for inflammatory bowel disease in the United States.
    Bewtra M, Su C, Lewis JD, et al. · Clin Gastroenterol Hepatol · 2007 · Background
    PubMed: PMID 17382602 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2006 (2 papers)

  1. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
    Van Assche G, Sandborn WJ, Feagan BG, et al. · Gut · 2006 · Background
    PubMed: PMID 16603634 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  2. Comparative proteomic studies on the pathogenesis of human ulcerative colitis.
    Hsieh SY, Shih TC, Yeh CY, et al. · Proteomics · 2006 · Background
    PubMed: PMID 16947118 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2005 (1 paper)

  1. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
    Daperno M, D'Haens G, Van Assche G, et al. · Gastrointest Endosc · 2005 · Background
    PubMed: PMID 15472670 · NCT03885713 (BioIBD) · Colitis, Ulcerative

2004 (3 papers)

  1. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.
    Loftus EV · Gastroenterology · 2004 · Background
    PubMed: PMID 15168363 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  2. Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli.
    Hardwidge PR, Rodriguez-Escudero I, Goode D, et al. · J Biol Chem · 2004 · Background
    PubMed: PMID 14988394 · NCT03885713 (BioIBD) · Colitis, Ulcerative
  3. Inflammatory bowel disease: the role of environmental factors.
    Danese S, Sans M, Fiocchi C, et al. · Autoimmun Rev · 2004 · Background
    PubMed: PMID 15288007 · NCT05313620 · Colitis, Ulcerative

2002 (2 papers)

  1. Platelets and thrombin generation.
    Monroe DM, Hoffman M, Roberts HR, et al. · Arterioscler Thromb Vasc Biol · 2002 · Background
    PubMed: PMID 12231555 · NCT05313620 · Colitis, Ulcerative
  2. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases.
    Barceló-Batllori S, André M, Servis C, et al. · Proteomics · 2002 · Background
    PubMed: PMID 11987129 · NCT03885713 (BioIBD) · Colitis, Ulcerative

1985 (1 paper)

  1. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis.
    Mielants H, Veys EM, Cuvelier C, et al. · J Rheumatol · 1985 · Background
    PubMed: PMID 3875721 · NCT03270501 (GO-GUT) · Axial Spondyloarthritis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).